Skip to main content
Erschienen in: Forensic Science, Medicine and Pathology 4/2021

04.11.2021 | Case Report

Death of a young woman with cyclic vomiting: a case report

verfasst von: Ingo von Both, Brittini Santos

Erschienen in: Forensic Science, Medicine and Pathology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

We report the death of a 22-year-old woman, with a 3½ year history of cyclic vomiting and cannabis use since age 14, who developed torsades de pointes cardiac arrythmia while being treated in the emergency room for nausea and vomiting. Resuscitation restored spontaneous cardiac circulation, however, due to post-cardiac arrest anoxic brain injury, she never regained consciousness and was declared brain dead 4 days later. Postmortem examination confirmed hypoxic-ischemic encephalopathy, in keeping with the in-hospital diagnosis of brain death. The heart was anatomically normal but showed signs of acute post-cardiopulmonary arrest reperfusion injury. As a consequence of limited survival in hospital in a neuro-vegetative state, early bronchopneumonia and isolated pulmonary thromboemboli were seen. Toxicological studies confirmed cannabis use, in addition to the presence of haloperidol and ondansetron. Genetic studies were performed to rule out a possible channelopathy and revealed a mutation in the MYBPC3 and RYR2 genes. Death in this woman with cannabinoid hyperemesis syndrome was attributed to a fatal cardiac arrhythmia complicating vomiting-induced hypokalemia and treatment with QT interval prolonging and potentially arrhythmogenic medications, with the identified cardiac genetic mutations listed as contributing factors. The emphasis of this report is a) to raise awareness that death can occur due to cyclic vomiting, b) provide a brief but practical overview of cannabinoid hyperemesis syndrome, c) describe the findings from our postmortem examination and come to the most reasonable cause and mechanism of death, d) comment on the risk factors associated with torsades de pointes cardiac arrythmia, and e) conclude that a complete postmortem examination is needed to exclude an anatomical or toxicological cause of death in cannabinoid hyperemesis syndrome, a disabling but preventable disorder.
Literatur
1.
Zurück zum Zitat Li BUK. Cyclic vomiting syndrome and abdominal migraine. Int Semin Pediatr Gastroenterol. 2000;9:1–9. Li BUK. Cyclic vomiting syndrome and abdominal migraine. Int Semin Pediatr Gastroenterol. 2000;9:1–9.
2.
Zurück zum Zitat Gee S. On fitful or recurrent vomiting. St Bartholomew Hosp Rev. 1882;18:1–6. Gee S. On fitful or recurrent vomiting. St Bartholomew Hosp Rev. 1882;18:1–6.
3.
Zurück zum Zitat Fleisher DR, Matar M. The cyclic vomiting syndrome: a report of 71 cases and literature review. J Pediatr Gastroenterol Nutr. 1993;17:361–9.PubMedCrossRef Fleisher DR, Matar M. The cyclic vomiting syndrome: a report of 71 cases and literature review. J Pediatr Gastroenterol Nutr. 1993;17:361–9.PubMedCrossRef
4.
Zurück zum Zitat Boles RG, Zaki EA, Lavenbarg T, Hejazi R, Foran P, Freeborn J, et al. Are pediatric and adult-onset cyclic vomiting syndrome (CVS) biologically different conditions? Relationship of adult-onset CVS with the migraine and pediatric CVS-associated common mtDNA polymorphisms 16519T and 3010A. Neurogastroenterol Motil. 2009;21:936-e72.PubMedCrossRef Boles RG, Zaki EA, Lavenbarg T, Hejazi R, Foran P, Freeborn J, et al. Are pediatric and adult-onset cyclic vomiting syndrome (CVS) biologically different conditions? Relationship of adult-onset CVS with the migraine and pediatric CVS-associated common mtDNA polymorphisms 16519T and 3010A. Neurogastroenterol Motil. 2009;21:936-e72.PubMedCrossRef
5.
Zurück zum Zitat Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53:1566–70.PubMedPubMedCentralCrossRef Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53:1566–70.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SK, Fleisher DR, et al. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008;20:269–84.PubMedCrossRef Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SK, Fleisher DR, et al. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008;20:269–84.PubMedCrossRef
7.
Zurück zum Zitat Pareek N, Fleisher DR, Abell T. Cyclic vomiting syndrome: what a gastroenterologist needs to know. Am J Gastroenterol. 2007;102:2832–40.PubMedCrossRef Pareek N, Fleisher DR, Abell T. Cyclic vomiting syndrome: what a gastroenterologist needs to know. Am J Gastroenterol. 2007;102:2832–40.PubMedCrossRef
8.
Zurück zum Zitat Prakash C, Clouse RE. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. Am J Gastroenterol. 1999;94:2855–60.PubMedCrossRef Prakash C, Clouse RE. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. Am J Gastroenterol. 1999;94:2855–60.PubMedCrossRef
9.
Zurück zum Zitat Li BU, Balint JP. Cyclic vomiting syndrome: evolution in our understanding of a brain-gut disorder. Adv Pediatr. 2000;47:117–60.PubMed Li BU, Balint JP. Cyclic vomiting syndrome: evolution in our understanding of a brain-gut disorder. Adv Pediatr. 2000;47:117–60.PubMed
10.
Zurück zum Zitat Herlihy JD, Reddy S, Shanker A, McCallum R. Cyclic vomiting syndrome: an overview for clinicians. Expert Rev Gastroenterol Hepatol. 2019;13:1137–43.PubMedCrossRef Herlihy JD, Reddy S, Shanker A, McCallum R. Cyclic vomiting syndrome: an overview for clinicians. Expert Rev Gastroenterol Hepatol. 2019;13:1137–43.PubMedCrossRef
11.
Zurück zum Zitat Drossman DA, Richter JE, Talley NJ, Thompson WG, Corrazziari E, Whitehead WE. The functional gastrointestinal disorders: diagnosis, pathophysiology and treatment. McLean, VA: Degnon Associates; 1994. Drossman DA, Richter JE, Talley NJ, Thompson WG, Corrazziari E, Whitehead WE. The functional gastrointestinal disorders: diagnosis, pathophysiology and treatment. McLean, VA: Degnon Associates; 1994.
12.
Zurück zum Zitat Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–92.PubMedCrossRef Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–92.PubMedCrossRef
13.
Zurück zum Zitat Suzuki H. The application of the Rome IV criteria to functional esophagogastroduodenal disorders in Asia. J Neurogastroenterol Motil. 2017;23:325–33.PubMedPubMedCentralCrossRef Suzuki H. The application of the Rome IV criteria to functional esophagogastroduodenal disorders in Asia. J Neurogastroenterol Motil. 2017;23:325–33.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262–79.CrossRef Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262–79.CrossRef
15.
Zurück zum Zitat Nourbakhsh M, Miller A, Gofton J, Jones G, Adeagbo B. Cannabinoid hyperemesis syndrome: Reports of fatal cases. J Forensic Sci. 2019;64:270–4.PubMedCrossRef Nourbakhsh M, Miller A, Gofton J, Jones G, Adeagbo B. Cannabinoid hyperemesis syndrome: Reports of fatal cases. J Forensic Sci. 2019;64:270–4.PubMedCrossRef
16.
Zurück zum Zitat Duncan M, Davison JS, Sharkey KA. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther. 2005;22:667–83.PubMedCrossRef Duncan M, Davison JS, Sharkey KA. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther. 2005;22:667–83.PubMedCrossRef
17.
Zurück zum Zitat Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol. 2014;722:134–46.PubMedCrossRef Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol. 2014;722:134–46.PubMedCrossRef
18.
Zurück zum Zitat Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology. 2001;121:767–74.PubMedCrossRef Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology. 2001;121:767–74.PubMedCrossRef
19.
Zurück zum Zitat Richards JR. Cannabinoid hyperemesis syndrome: A disorder of the HPA axis and sympathetic nervous system? Med Hypotheses. 2017;103:90–5.PubMedCrossRef Richards JR. Cannabinoid hyperemesis syndrome: A disorder of the HPA axis and sympathetic nervous system? Med Hypotheses. 2017;103:90–5.PubMedCrossRef
20.
Zurück zum Zitat Lundberg DJ, Daniel AR, Thayer SA. Delta(9)-tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture. Neuropharmacology. 2005;49:1170–7.PubMedCrossRef Lundberg DJ, Daniel AR, Thayer SA. Delta(9)-tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture. Neuropharmacology. 2005;49:1170–7.PubMedCrossRef
21.
Zurück zum Zitat Darmani NA. Cannabinoid-induced hyperemesis: A conundrum from clinical recognition to basic science mechanisms. Pharmaceuticals (Basel). 2010;3:2163–77.CrossRef Darmani NA. Cannabinoid-induced hyperemesis: A conundrum from clinical recognition to basic science mechanisms. Pharmaceuticals (Basel). 2010;3:2163–77.CrossRef
23.
25.
Zurück zum Zitat Kim HS, Anderson JD, Saghafi O, Heard KJ, Monte AA. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med. 2015;22:694–9.PubMedPubMedCentralCrossRef Kim HS, Anderson JD, Saghafi O, Heard KJ, Monte AA. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med. 2015;22:694–9.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: Diagnosis, pathophysiology, and treatment-a systematic review. J Med Toxicol. 2017;13:71–87.PubMedCrossRef Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: Diagnosis, pathophysiology, and treatment-a systematic review. J Med Toxicol. 2017;13:71–87.PubMedCrossRef
28.
Zurück zum Zitat Matheson J, Le Foll B. Cannabis legalization and acute harm from high potency cannabis products: A narrative review and recommendations for public health. Front Psychiatry. 2020;11:591979. Matheson J, Le Foll B. Cannabis legalization and acute harm from high potency cannabis products: A narrative review and recommendations for public health. Front Psychiatry. 2020;11:591979.
29.
Zurück zum Zitat Soota K, Lee Y-J, Schouweiler K, Keeney M, Nashelsky M, Holm A. Cases of death secondary to cannabinoid hyperemesis syndrome. Am J Gastroenterol. 2016;111(Abstract 2217):S1063. Soota K, Lee Y-J, Schouweiler K, Keeney M, Nashelsky M, Holm A. Cases of death secondary to cannabinoid hyperemesis syndrome. Am J Gastroenterol. 2016;111(Abstract 2217):S1063.
31.
Zurück zum Zitat Cheungpasitporn W, Suksaranjit P, Chanprasert S. Pathophysiology of vomiting-induced hypokalemia and diagnostic approach. Am J Emerg Med. 2012;30:384.PubMedCrossRef Cheungpasitporn W, Suksaranjit P, Chanprasert S. Pathophysiology of vomiting-induced hypokalemia and diagnostic approach. Am J Emerg Med. 2012;30:384.PubMedCrossRef
34.
35.
Zurück zum Zitat White JK, Carver J. Self-induced vomiting as a probable mechanism of an isolated hyoid bone fracture. Am J Forensic Med Pathol. 2012;33:170–2.PubMedCrossRef White JK, Carver J. Self-induced vomiting as a probable mechanism of an isolated hyoid bone fracture. Am J Forensic Med Pathol. 2012;33:170–2.PubMedCrossRef
38.
Zurück zum Zitat Widimsky P. Hypokalemia and the heart. e-Journal of Cardiology Practice. 2008;7. Widimsky P. Hypokalemia and the heart. e-Journal of Cardiology Practice. 2008;7.
40.
Zurück zum Zitat Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: What is new in 2018? Curr Gastroenterol Rep. 2018;20:46.PubMedCrossRef Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: What is new in 2018? Curr Gastroenterol Rep. 2018;20:46.PubMedCrossRef
42.
Zurück zum Zitat Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G. Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol. 2017;12:210–22.PubMedCrossRef Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G. Drug-induced QT interval prolongation in the intensive care unit. Curr Clin Pharmacol. 2017;12:210–22.PubMedCrossRef
43.
Zurück zum Zitat Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5:E8-16.PubMedCrossRef Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5:E8-16.PubMedCrossRef
44.
Zurück zum Zitat Lapoint J, Meyer S, Yu CK, Koenig KL, Lev R, Thihalolipavan S, et al. Cannabinoid hyperemesis syndrome: Public health implications and a novel model treatment guideline. West J Emerg Med. 2018;19:380–6.PubMedCrossRef Lapoint J, Meyer S, Yu CK, Koenig KL, Lev R, Thihalolipavan S, et al. Cannabinoid hyperemesis syndrome: Public health implications and a novel model treatment guideline. West J Emerg Med. 2018;19:380–6.PubMedCrossRef
45.
Zurück zum Zitat Portman D, Donovan KA. Cannabinoid hyperemesis syndrome: A case report of a confounding entity in oncology care. J Oncol Pract. 2018;14:333–4.PubMedCrossRef Portman D, Donovan KA. Cannabinoid hyperemesis syndrome: A case report of a confounding entity in oncology care. J Oncol Pract. 2018;14:333–4.PubMedCrossRef
46.
Zurück zum Zitat Witsil JC, Mycyk MB. Haloperidol, a novel treatment for cannabinoid hyperemesis syndrome. Am J Ther. 2017;24:e64-7.PubMedCrossRef Witsil JC, Mycyk MB. Haloperidol, a novel treatment for cannabinoid hyperemesis syndrome. Am J Ther. 2017;24:e64-7.PubMedCrossRef
47.
Zurück zum Zitat Jones JL, Abernathy KE. Successful treatment of suspected cannabinoid hyperemesis syndrome Using haloperidol in the outpatient setting. Case Rep Psychiatry. 2016;2016:3614053.PubMedPubMedCentral Jones JL, Abernathy KE. Successful treatment of suspected cannabinoid hyperemesis syndrome Using haloperidol in the outpatient setting. Case Rep Psychiatry. 2016;2016:3614053.PubMedPubMedCentral
48.
Zurück zum Zitat Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. SciWorld J. 2012;2012:212178. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. SciWorld J. 2012;2012:212178.
49.
Zurück zum Zitat Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479–87.PubMedPubMedCentralCrossRef Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479–87.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149:139–52.CrossRef Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149:139–52.CrossRef
51.
Zurück zum Zitat Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci. 2010;55:3113–9.PubMedCrossRef Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci. 2010;55:3113–9.PubMedCrossRef
52.
Zurück zum Zitat Nicolson SE, Denysenko L, Mulcare JL, Vito JP, Chabon B. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. Psychosomatics. 2012;53:212–9.PubMedCrossRef Nicolson SE, Denysenko L, Mulcare JL, Vito JP, Chabon B. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. Psychosomatics. 2012;53:212–9.PubMedCrossRef
53.
Metadaten
Titel
Death of a young woman with cyclic vomiting: a case report
verfasst von
Ingo von Both
Brittini Santos
Publikationsdatum
04.11.2021
Verlag
Springer US
Erschienen in
Forensic Science, Medicine and Pathology / Ausgabe 4/2021
Print ISSN: 1547-769X
Elektronische ISSN: 1556-2891
DOI
https://doi.org/10.1007/s12024-021-00410-z

Weitere Artikel der Ausgabe 4/2021

Forensic Science, Medicine and Pathology 4/2021 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …